Neuroimaging

AHEAD STUDY IS FIRST TO TEST LECANEMAB TO DELAY OR PREVENT ALZHEIMER'S DISEASE SYMPTOMS AT THE STAGE OF PRECLINICAL AD

Retrieved on: 
onsdag, november 2, 2022
Amyloid, Plasma, Population, Headquarters, Clinical trial, Brain, Biomarker, Ageing, Research, PET, NIH, Harvard University, Risk, National Institute, Disease, Harvard Medical School, Safety, Neuroimaging, National, AD, Clarity, Biogen, BAN2401, Eisai, Dementia, NIA, Neurology, MCI, USC, ACTC, Multimedia, Clinical professor, SAN, Mayo Clinic, National Institute on Aging, Amnesia, Positron emission tomography, Medical imaging, Pharmaceutical industry, Online shopping, Alzheimer's disease

The AHEAD Study is the first ever clinical trial to test the effect of lecanemab (investigational antibody) in people who have no cognitive symptoms of Alzheimer's disease (AD), but in whom biomarker tests indicate amyloid is present in the brain, known as "preclinical" AD.

Key Points: 
  • The AHEAD Study is the first ever clinical trial to test the effect of lecanemab (investigational antibody) in people who have no cognitive symptoms of Alzheimer's disease (AD), but in whom biomarker tests indicate amyloid is present in the brain, known as "preclinical" AD.
  • The AHEAD Study is also the first AD trial to recruit people as young as 55 years old who are at risk of developing symptoms of AD as they get older.
  • The AHEAD Study will test whether the clinical effects reported in the Clarity AD clinically symptomatic population are similar in the AHEAD preclinical AD population.
  • "The AHEAD Study is testing lecanemab in a much earlier stage of AD than the Clarity AD trial," said Dr. Reisa Sperling, professor of neurology at Harvard Medical School, and co-principal investigator of the AHEAD Study.

MIM Software Inc. Receives Health Canada Approval for AI Auto-Contouring Software

Retrieved on: 
tisdag, november 1, 2022
Nuclear medicine, Clinic, OH, Health, Contour, Hospital, Cardiac imaging, AI, Workflow, Health Canada, Multimedia, Environment, Software, Radiation therapy, Medical device, Medicine, Neuroimaging, Radiology

CLEVELAND, Nov. 1, 2022 /PRNewswire/ -- MIM Software Inc., a leading global provider of medical imagingsoftware, announced today it has received approval from Health Canada for its AI auto-contouring solution, Contour ProtgAI.

Key Points: 
  • CLEVELAND, Nov. 1, 2022 /PRNewswire/ -- MIM Software Inc., a leading global provider of medical imagingsoftware, announced today it has received approval from Health Canada for its AI auto-contouring solution, Contour ProtgAI.
  • Health Canada has approved Contour ProtgAI AI auto-contouring software, for quicker simulation to treatment times.
  • Contour ProtgAI seamlessly integrates into any department's workflow and can be rapidly implemented into virtually any environment via local deployment.
  • MIM Software sells its products globally to imaging centers, hospitals, specialty clinics, research organizations, and pharmaceutical companies.

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

Retrieved on: 
tisdag, oktober 4, 2022
Algorithm, Concussion, Senior advisor, MT3, OPKO Health, Family, Prognosis, Diagnosis, BDNF, Posture, Psychology, Book, Sports medicine, Medtech, Brainbox, NIH, Patent, Athlete, GFAP, MRI, Developing Solutions, Inc, TBI, Neuroimaging, Health, László, J&J, Cuban medical internationalism, PTO, Solution, NFL, University, Unitus Seed Fund, UCLA School of Dentistry, Stryker, Biomarker, LECOM Health Challenge, Forme, Partner, Risk, Intellectual property, Board, Marketing, NSE, NRGN, Medical imaging, Pharmaceutical industry, Medical device, Biology, Medicine

RICHMOND, Va., Oct. 4, 2022 /PRNewswire/ -- BRAINBox Solutions, Inc announced today that the U.S. Patent & Trademark Office (PTO) issued a notice of allowance for a patent covering methods for detection of mild traumatic brain injury (mTBI), also known as concussion, using Brain Derived Neurotrophic Factor (BDNF). BDNF is an important component of the biomarker panel in the multi-modal diagnostic prognostic and prognostic solutions the company is developing for mTBI.

Key Points: 
  • "BRAINBox's test is the first to integrate blood biomarkers with functional testing for both the diagnosis and prognosis of mild TBI," said Donna Edmonds, BRAINBox Solutions' Chief Executive Officer.
  • "The new BDNF patent is an important addition to our broad, worldwide portfolio of patents covering biomarkers related to various aspects of diagnostic use.
  • The newly allowed patent is based on BRAINBox Solutions' discovery that a decrease in blood levels of BDNF alone are sensitive and specific in the detection of mild TBI.
  • BRAINBox Solutions is developing the first AI enabled, multi-modality approach for the diagnosis and prognosis of Mild Traumatic Brain Injury, commonly referred to as a concussion.

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

Retrieved on: 
tisdag, september 20, 2022
Adult, Central nervous system, ASX, Neurodegeneration, Safety, Movement, Spinal cord, Blood pressure, Brain, FDA, Disease, MSA, Food, Neuroimaging, Dysautonomia, Autonomic nervous system, IND, Parkinson's disease, Company, European Commission, Rigidity, Therapy, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Physician, ATHE, CEO, Pathology, Multiple system atrophy, NASDAQ, SAN, ATH, Pharmacokinetics, Royal commission, Multimedia, Drug discovery, View, Death, Pharmaceutical industry, Medical imaging, Parkinsonism, Alterity

MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to allow evaluation of ATH434 in individuals with Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder. The approval of this IND authorizes Alterity to conduct its Phase 2 clinical trial in the U.S.

Key Points: 
  • The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
  • The study is expected to enroll approximately 60 adult patients to receive one of two dose levels of ATH434 or placebo.
  • ATH434 has been granted Orphan designation for the treatment of MSA by the U.S. FDA and the European Commission.
  • Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement.

Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning

Retrieved on: 
måndag, augusti 22, 2022
Neoplasm, COVID-19, CEO, Technology, 3D, Cancer, XV, Research, OH, Alpha Sigma Tau, Brain, Xi, Solution, Software, Risk, Cardiac imaging, Data management, Radiation therapy, SEC, Nuclear medicine, U.S. Securities and Exchange Commission, Method, 100,000, Urology, GLOBE, Health, Pancreas, Nasdaq, Radiation, Annual report, MIM, Private Securities Litigation Reform Act, Vii, Alpha Tau Delta, Patient, Pharmaceutical industry, Medical imaging, Radiology, Tel Aviv University, Brachytherapy, Neuroimaging, Alpha

JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, and MIM Software Inc. (MIM Software), a leading global provider of medical imaging software, announced a collaboration between the two companies to provide treatment planning software for clinical sites using the Alpha DaRT therapy.

Key Points: 
  • JERUSALEM and CLEVELAND, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, and MIM Software Inc. (MIM Software), a leading global provider of medical imaging software, announced a collaboration between the two companies to provide treatment planning software for clinical sites using the Alpha DaRT therapy.
  • Under the terms of the agreement, the parties will collaborate on the use of MIMs software suite, including MIM Symphony and MIMcloud, for development of new features and support for the Alpha DaRT across multiple potential indications, integration into all clinical trials involving the Alpha DaRT, and bundling the MIM software with the Alpha DaRT for future commercial sales in territories where the Alpha DaRT and MIMs software are both approved.
  • The MIM Symphony treatment planning software guides clinicians through an easy step-by-step process to place Alpha DaRT sources precisely and create a patient-personalized treatment plan.
  • Our collaboration with Alpha Tau is an excellent opportunity for MIM to impact radiotherapy and patient outcomes, said Andy Nelson, CEO of MIM Software.

Annovis Bio to Participate on Alzheimer's Association International Conference Panel

Retrieved on: 
måndag, augusti 1, 2022
AAIC, Neurodegeneration, Translational neuroscience, Gian Maria Annovi, Reno 1868 FC, University, Company, Security (finance), LinkedIn, Sunnybrook Research Institute, Brain, Doctor of Science, Neuroimaging, Panel, U.S. Securities and Exchange Commission, Human, Interest, Biomarker, National Institute of General Medical Sciences, Memory, Cognition, Pathology, Case Western Reserve University, Twitter, CEO, Parkinson's disease, Risk, Conference, Central nervous system, AD, Annual report, Toxicology, Toxicity, Axonal transport, Forward-looking statement, NYSE, PD, National Institute, Pharmacology, Principal, Inflammation, MD, Patient, Pharmacokinetics, Systems biology, AM, Pharmaceutical industry, Medical imaging, Medicine, Psychiatry, Alzheimer's disease

BERWYN, Pa., Aug. 1, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced that Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis, will be participating on the Systems Biology of Alzheimer's Disease Panel at the Alzheimer's Association International Conference (AAIC).

Key Points: 
  • The panel will focus on the need and underpinning rationale for advancing novel therapeutic approaches for Alzheimer's disease.
  • The panel is scheduled to take place on August 4th, 2022, at 8-9:15 AM Pacific Time / 11 AM - 12:15 PM Eastern Time.
  • Interested parties may access a live panel discussion through the AAIC 2022 conference site and archived webcast of the presentation on the Company's investor relations website at: www.annovisbio.com .
  • For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter .

Viz.ai Partners with Hyperfine to Enable New MR Imaging and Workflow Paradigm

Retrieved on: 
tisdag, juli 26, 2022
Health, Medical Devices, Technology, Health Technology, Software, Radiology, Artificial Intelligence, MRI, Algorithm, Diagnosis, Time, Mortality, Neuroimaging, Physician, U.S. Securities and Exchange Commission, Decision-making, Doctor of Philosophy, Health, Hospital, Partnership, Associate, Private Securities Litigation Reform Act, Marketing, University Medical Center, Deep learning, Income, US, Disease, COVID-19, US FDA, EMEA, Multimedia, Neuro, Machine learning, Mission statement, Magnetic resonance imaging, Technology, Â, FDA, Ohio State University Wexner Medical Center, Patient, Transport, ER, Nasdaq, Security (finance), Stroke, Humanitarian use licenses, Forbes, Growth, Swoop, AI, ICU, Surgery, Medical imaging, MD, Hyperfine structure

Together, they will bring MRI to the patients bedside and deliver valuable insights to the clinicians fingertips for timely decision making.

Key Points: 
  • Together, they will bring MRI to the patients bedside and deliver valuable insights to the clinicians fingertips for timely decision making.
  • Swoop, the worlds first MR imaging system capable of providing neuroimaging at the point of care, expands patient access to MRI by bringing imaging to the bedside.
  • With this partnership, we will be able to combine Vizs intelligent care coordination platform and leading image viewer with the Hyperfine Swoop Portable MR Imaging System.
  • Hyperfine, Inc. is the groundbreaking medical device company that created Swoop, the worlds first US FDA-cleared portable MRI system.

Inscopix Announces Cloud-Based IDEAS™ Platform for Neuroscience Research with New Neural Circuit Workflow

Retrieved on: 
torsdag, juli 7, 2022
Neurology, Software, Biometrics, Biotechnology, Health, Data Management, Health Technology, Technology, Patient, CEO, Neuroimaging, Research, Workflow, Brain, FENS, Brain mapping, Lists of diseases, Optogenetics, CSO, Publication, Therapy, IDEAS, Neuron, Database, Data science, Method, Medical imaging, Mobile phone, Music

Inscopix, Inc., a neuroscience company helping decode the brain for tomorrows treatments, announced that it is launching the Inscopix Data Exploration, Analysis and Sharing (IDEAS) Platform to help neuroscience research groups improve how they analyze and organize neuroscience data.

Key Points: 
  • Inscopix, Inc., a neuroscience company helping decode the brain for tomorrows treatments, announced that it is launching the Inscopix Data Exploration, Analysis and Sharing (IDEAS) Platform to help neuroscience research groups improve how they analyze and organize neuroscience data.
  • Initially launched in December 2021 as an enterprise-friendly solution, the cloud-based IDEAS Platform is the first-of-its-kind turnkey solution for multimodal preclinical research data and a powerful database solution with scalable compute infrastructure.
  • The development and launch of IDEAS is perhaps the most significant product milestone for Inscopix since the invention and launch of the miniscope, said Kunal Ghosh, Ph.D., CEO at Inscopix.
  • Inscopix is a brain mapping platform company focused on decoding the mind to better understand and address all neurological disorders.

CLEVELAND.COM AND THE PLAIN DEALER NAMES MIM SOFTWARE, INC A WINNER OF THE NORTHEAST OHIO TOP WORKPLACES 2022 AWARD

Retrieved on: 
söndag, juni 26, 2022
Nuclear medicine, Health, U.S. News & World Report, View, Radiation therapy, LLC, Software, Organization, OH, U.S. News & World Report Best Hospitals Rankings, Cardiac imaging, Culture, Human, News, Multimedia, Hospital, Management, Radiology, Neuroimaging

BEACHWOOD, Ohio, June 26, 2022 /PRNewswire/ -- MIM Software, Inc has been awarded a Top Workplaces 2022 honor by the cleveland.com and The Plain Dealer Top Workplaces.

Key Points: 
  • BEACHWOOD, Ohio, June 26, 2022 /PRNewswire/ -- MIM Software, Inc has been awarded a Top Workplaces 2022 honor by the cleveland.com and The Plain Dealer Top Workplaces.
  • The list is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner Energage, LLC .
  • "Companies need to authentically represent their brand to job-seekers," said Eric Rubino, Energage CEO.
  • MIM Software is used in 16 of the top 20 hospitals listed in the U.S. News & World Report Hospital Rankings & Ratings.

Yale’s Department of Psychiatry Chair to Join Clearmind Medicine

Retrieved on: 
tisdag, juni 21, 2022
NIAAA, OTC Markets Group, Neuroimaging, Association, Department, Neuronus IBRO & IRUN Neuroscience Forum, Yale New Haven Hospital, Therapy, Translational neuroscience, American Association, Ketamine, Alcoholism, Psychopharmacology, Schizophrenia, National Center for Advancing Translational Sciences, The Company, Yale University, Translational research, Coronavirus Scientific Advisory Board (Turkey), Hebrew University of Jerusalem, Depression, Research, American Association for Laboratory Animal Science, Biological Psychiatry (journal), PTSD, Bar-Ilan University, CSE, Post-traumatic stress disorder, University, Eleazar Sukenik, Acquisition, Chicago (franchise), Mental health, FSE, GLOBE, Pharmaceutical industry, Medicine, Psychology, Neuroscience, Science, Psychiatry, Engineering

VANCOUVER, June 21, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the appointment to its Scientific Advisory Board of John Krystal, Chair of the Psychiatry Department at Yale University’s School of Medicine.

Key Points: 
  • He is best known for leading the discovery of the rapid antidepressant effects of ketamine.
  • Dr. Krystal is a Professor of Translational Research; Psychiatry, Neuroscience, and Psychology; he chairs the Department of Psychiatry at Yale University; and he is Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital.
  • He is a member of the U.S. National Academy of Medicine and a Fellow of the American Association for the Advancement of Science.
  • Clearmind has established a research collaboration with the Hebrew University of Jerusalem and Bar Ilan University.